Clinical Trial Update: The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update indicates XS228CN-derived motor neuron progenitor cells are being tested in ALS for safety, tolerability, and preliminary efficacy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• XS228CN-derived motor neuron progenitor cells (XS228CN-derived motor neuron progenitor cells)

Snippet

Sponsor: XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. | Conditions: Amyotrophic Lateral Sclerosis (ALS) | Phase 1 | Status: RECRUITING